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Abstract: Although smallpox has been eradicated globally, the potential use of the smallpox virus in
bioterrorism indicates the importance of stockpiling smallpox vaccines. Considering the advantages
of microneedle-based vaccination over conventional needle injections, in this study, we examined
the feasibility of microneedle-based smallpox vaccination as an alternative approach for stockpiling
smallpox vaccines. We prepared polylactic acid (PLA) microneedle array patches by micromolding
and loaded a second-generation smallpox vaccine on the microneedle tips via dip coating. We evalu-
ated the effect of excipients and drying conditions on vaccine stability in vitro and examined immune
responses in female BALB/c mice by measuring neutralizing antibodies and interferon (IFN)-γ-
secreting cells. Approximately 40% of the virus titer was reduced during the vaccine-coating process,
with or without excipients. At−20 ◦C, the smallpox vaccine coated on the microneedles was stable up
to 6 months. Compared to natural evaporation, vacuum drying was more efficient in improving the
smallpox vaccine stability. Microneedle-based vaccination of the mice elicited neutralizing antibodies
beginning 3 weeks after immunization; the levels were maintained for 12 weeks. It significantly
increased IFN-γ-secreting cells 12 weeks after priming, indicating the induction of cellular immune
responses. The smallpox-vaccine-coated microneedles could serve as an alternative delivery system
for vaccination and stockpiling.
Keywords: smallpox; microneedle; vaccinia virus; coating; stability; immune response
1. Introduction
Smallpox is caused by the variola virus, an enveloped double-stranded DNA virus
belonging to the genus Orthopoxvirus. It is a highly contagious and morbid disease with ap-
proximately 30% mortality [1–3]. Following an organized vaccination program, the World
Health Organization declared the global eradication of the disease in 1980. In South
Korea, the smallpox vaccination program has been discontinued since 1979. However,
there is an increased possibility that the smallpox virus could be used as a bioterrorism
weapon, thus indicating the need for stockpiling smallpox vaccine [4,5]. Although first-
generation smallpox vaccines saved millions of lives and achieved the eradication of
smallpox, they presented limitations such as serious adverse events, unwanted immune
responses to calf-derived materials, and bovine prion transmission [6]. To mitigate the side
effects of the first-generation vaccines, a cell culture-derived smallpox vaccine (CJ-50300)
was developed by a Korean pharmaceutical company and licensed by the Korea Food and
Drug Administration in 2008 [7]. This vaccine is inoculated by puncturing the skin using a
bifurcated needle [8,9]; however, vaccination using bifurcated needles has raised concerns
regarding needle-related injuries and disease transmission, as well as biohazardous sharp
waste generation.
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Microneedles are microstructures that facilitate the delivery of molecules into the
epidermal and/or dermal layer of the skin and can be used as a highly promising delivery
system for vaccination [10–14]. There are different types of microneedles, including coated
microneedles, dissolving microneedles, and hollow microneedles, depending on the mor-
phology and delivery strategy. Typically, microneedles exhibit a conical or pyramidal shape
with 1:1~1:3 aspect ratio (width to height), and they are formulated using biocompatible
materials via various microfabrication techniques [10,15–18]. Although most vaccines have
been administered through either intramuscular (IM) or subcutaneous (SC) routes using
hypodermic needles [19,20], cutaneous immunization could serve as a superior effective
approach for preventing pathogenic infection and facilitating dose sparing for multiple
vaccines compared to IM or SC administration [21–24]. The skin is an attractive site for
vaccination due to the abundance of antigen-presenting cells (APCs), including Langerhans
cells, dermal dendritic cells, macrophages, and monocytes, as well as accessory cells such
as keratinocytes [21,25]. These APCs recognize, uptake, and present foreign antigens to T-
and B-cells in the draining lymph nodes to initiate adaptive immune responses. In addition
to the advantage of cutaneous immunization, microneedles can resolve several issues
associated with the use of hypodermic needles, such as pain and needlestick injuries, as
well as the requirement for trained personnel, appropriate needle disposal, and expensive
logistics. Moreover, solidified vaccines contained in microneedles are considerably more
stable at increased temperatures than liquid-state vaccines, thereby reducing economic
burden related to vaccine storage, transport, and distribution [26–30].
On the basis of the results from previous studies, we hypothesized that smallpox
vaccination using microneedles would address the problems associated with the use of
bifurcated needles and induce both humoral and cell-mediated immune responses [31,32].
In this study, we selected a coated microneedle system, among various microneedle plat-
forms, for smallpox vaccination due to its higher mechanical strength, faster drug delivery,
and easier fabrication process compared with other microneedle types [33,34]. We prepared
second-generation smallpox-vaccine-coated microneedles by exploring various formula-
tions, fabrication processes, and storage conditions and evaluated their efficacy in mice by
measuring neutralizing antibodies and interferon (IFN)-γ secreting cells.
2. Materials and Methods
2.1. Vaccina Virus Vaccine
The second-generation vaccinia virus vaccine (CJ-50300) was kindly provided by the
Korea National Institute of Health (KNIH). CJ-50300 was derived from the vaccinia virus
strain ATCC VR-118 (originating from the New York City Board of Health vaccinia strain),
which was adapted to replicate in MRC-5 cells under serum-free conditions without plaque
purification [7].
2.2. Preparation of Coating Solution
In this study, pharmaceutical-grade polyvinyl alcohol (PVA; Gohsenol™ EG-30 PW;
Nippon Gohsei Europe GmbH, Dusseldorf, Germany) and trehalose (Sigma-Aldrich Korea,
Yongin, South Korea) were used as excipients. Four different coating solutions were
prepared in phosphate-buffered saline (PBS; pH 7.4; Thermo Fisher Scientific, Waltham,
MA, USA), as summarized in Table 1. The prepared solutions were stored at 4 ◦C for 2 h
prior to use.
2.3. Fabrication of Coated Microneedles
A microneedle master, composed of 97 obelisk microneedles (800 µm height, 370 µm
width, 400 µm gap between needles) in a circular base (1 cm diameter), was prepared by
micromilling [35]. A microneedle mold was prepared by casting polydimethylsiloxane
(PDMS, Sylgard® 184; Dow Corning, Midland, MI, USA) over the master followed by cur-
ing at 70 ◦C for 1 h. Polymeric microneedles were subsequently replicated through casting
polylactic acid (PLA; DURECT Corp., Birmingham, AL, USA) into the mold. PLA pellets
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were stacked on the mold and melted at 190 ◦C for 30 min in a vacuum oven. Bubbles gen-
erated during the PLA casting were removed by applying vacuum (approximately 70 kPa)
several times. Once the molten PLA was filled in the mold cavity, the mold was cooled at
22 ± 2 ◦C. The PLA microneedles were subsequently detached from the mold.
Table 1. Composition of coating solutions.
Formulation Smallpox Vaccine PVA Trehalose PBS
F1 2.5 × 107 PFU − − 300 µL
F2 2.5 × 107 PFU 5% (w/v) − 300 µL
F3 2.5 × 107 PFU − 15% (w/v) 300 µL
F4 2.5 × 107 PFU 5% (w/v) 15% (w/v) 300 µL
A predetermined amount of vaccine was loaded on the microneedles through dip
coating using a homemade apparatus. The coating solution, described in Table 1, was filled
in a 400 µm-deep coating well, and the PLA microneedle attached to the linear actuator
was dipped in the coating well at 1 mm/s for 1 s and pulled up at 1 mm/s. The coated mi-
croneedle was subsequently dried for 1 h either under ambient conditions (approximately
24 ◦C and 40% relative humidity) or under vacuum (5 × 10−4 Torr). Figure 1 shows the
overall fabrication process and the fabricated microneedles.
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Figure 1. Fabrication process and results. (a) polydimethylsiloxane (PDMS) mold preparation, (b) polylactic acid (PLA)
pellet loading, (c) PLA melt casting, (d) PLA microneedle demolding, (e) dip coating, (f) drying, (g) PLA microneedles,
and (h) vaccine-coated microneedles.
To maintain the sterility of the smallpox vaccine-coated microneedles during fabrica-
tion as best as possible, all fabrication processes, including coating solution preparation,
coating, and drying, were carried out in a biosafety cabinet, which was rigorously disin-
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fected prior to microneedle fabrication. All materials, equipment, and consumables used
for microneedle fabrication were also sterilized by a suitable technique, such as autoclave
and filtration, considering the compatibility with the sterilization process.
2.4. In Vitro Vaccine Stability Test
The stability of vaccinia virus vaccine during drying and storage was examined
in vitro. The plaque assay was used for measuring virus titers. To determine the vaccine
stability upon drying, 10 µL of each formulation, described in Table 1, was spread on PLA
surface having a diameter of 10 mm, which mimics the surface of the PLA microneedle,
dried under ambient conditions, and reconstituted for the assay. We added 700 µL of PBS
to F1 and F2, and 10 µL of each sample was used for the measurement (i.e., the estimated
viral titer of each sample was 2.5 × 105 PFU).
To examine the storage stability, vaccine-coated microneedles were prepared using
each formulation, stored either at 4 ◦C or−20 ◦C for 1, 3, and 6 months, and were subjected
to the assay.
For the plaque assay, the virus was recovered from the prepared samples through
immersion of the samples in 1 mL of cell culture media (Opti-MEM™; Gibco, Carlsbad,
CA, USA) at 4 ◦C for 2 h. Serial dilutions of the recovered virus solution were subse-
quently added to Vero cells in a 12-well plate. The final overlay was performed with
0.2% low-melting agarose (SeaPlaque™, Lonza, Basel, Switzerland) in Opti-MEM™, con-
taining 2% fetal bovine serum (FBS; Gibco). The cells were cultured at 37 ◦C for 3 days,
fixed, and stained with crystal violet mixture (0.13% crystal violet, 8% formaldehyde, 5%
ethanol). Plaques were then counted under an optical microscope (ECLIPSE TS100; Nikon,
Tokyo, Japan).
2.5. Animals and Vaccine Administration
Six-week-old female Balb/c mice were purchased from Orient Bio Inc. (Seongnam,
South Korea) and maintained under specific pathogen-free conditions in the experimental
facility at the International Vaccine Institute (IVI; Seoul, South Korea); they received
sterilized food and water ad libitum. All animal experiments described were approved by
the IVI Institutional Animal Care and Use Committees (approved code: PN 2020-012).
Prior to microneedle vaccination, the hair on the dorsal skin of the mice were removed
using a depilatory cream (Nair™; Church and Dwight, Trenton, NJ, USA). Five mice
per group were subsequently treated with either smallpox-vaccine-coated microneedles
(mean titer: 3.3 × 105 PFU) or blank microneedles. The microneedles were applied to the
hair-free region using an adhesive patch and thumb pressure and were further affixed to
the skin with a clamp for 30 min. Serum samples were collected from the retro-orbital
plexus 1, 3, 6, 9, and 12 weeks after immunization.
2.6. Analysis of Neutralizing Antibody Responses
For analyzing neutralizing antibodies against the vaccinia virus, the plaque reduction
neutralization test (PRNT) was performed. The PRNT50 titer was determined using the
highest serum dilution inhibiting 50% or more of the plaques relative to the number of
plaques in the absence of test serum. Serum samples were heat-inactivated at 56 ◦C for
30 min before use. Two-fold serial dilutions of the inactivated serum sample and virus
samples containing 100 PFU were mixed and incubated at 37 ◦C for 2 h. Vero cells in
24-well plates (80–90% confluent, approximately 4 × 104 cells/well) were treated with the
incubated virus–serum mixtures. The final overlay was performed using 0.2% low-melting
agarose in Opti-MEM™ media containing 2% FBS. The cells were cultured at 37 ◦C for
3 days, and the plaques were counted after fixing and staining the cells with crystal violet
mixture (0.13% crystal violet, 8% formaldehyde, and 5% ethanol).
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2.7. Analysis of Cell-Mediated Immune Responses
To examine cell-mediated immune responses, IFN-γ-secreting cells in splenocytes
of the immunized mice were counted using the enzyme-linked immunospot (ELISPOT)
assay (Mabtech, Inc., Cincinnati, OH, USA), according to manufacturer’s instructions. Sin-
gle cell suspensions from the spleen tissue were obtained by mashing the spleen through
the cell strainer using the plunger end of the syringe, and erythrocytes were lysed us-
ing Ammonium-Chloride-Potassium (ACK) buffer. For ELISPOT assay, 96-well plates
(coated with capture antibody) were blocked with RPMI 1640 supplemented with 10% FBS;
5 × 105 cells from each group were plated and stimulated with UV-inactivated vaccinia
virus at 37 ◦C for 48 h in a 5% CO2 incubator. 3,3′,5,5′-tetramethylbenzidine (TMB) peroxi-
dase substrate was used for color development, and IFN-γ-secreting cells were counted
and visualized using an ELISPOT reader (ImmunoSpot®; Cellular Technology Limited,
Cleveland, OH, USA). Data were analyzed by one-way analysis of variance (ANOVA) using
GraphPad Prism software, version 8.0 (GraphPad Software Inc., San Diego, CA, USA).
2.8. Statistical Analysis
To determine statistical significance, a two-tailed Student’s t-test was performed when
comparing two different conditions, and the one-way ANOVA was used when comparing
multiple groups. A value of p < 0.05 was considered statistically significant.
3. Results and Discussion
3.1. Influence of Fabrication Process on Vaccine Stability
Commercial smallpox vaccine is a lyophilized live virus vaccine and needs to be
maintained at −20 ◦C. To prepare smallpox-vaccine-coated microneedles, the vaccine is
thawed, mixed with excipients, coated on the tip of microneedles, and solidified. Dur-
ing this fabrication process, the vaccine experiences phase transition twice (i.e., solid to
liquid during thawing and liquid to solid during coating), which often causes vaccine
instability. Therefore, it is necessary to examine the change in vaccine stability due to
phase transition.
We first examined the stability of the vaccine with or without PVA (F1 and F2 in Table 1)
by measuring the viral titers. PVA was used as a viscosity enhancer, which is required for
coating. As shown in Figure 2, there were no significant differences between the virus titers
of F1 and F2 in the liquid state. However, solidification caused approximately 40% decrease
in the virus titer for both cases. We next examined the effect of trehalose, a widely used
vaccine stabilizer, on the stability of the smallpox vaccine during solidification. However,
addition of trehalose produced no improvement in vaccine stability. This result suggests
that the thawing and mixing processes minimally affect vaccine stability, whereas the
drying process substantially reduced the viability of the vaccinia virus, regardless of the
use of PVA and trehalose.
As the stress induced during drying varies depending on the drying method, we next
examined two drying methods, natural evaporation drying and vacuum drying, which have
been commonly used for microneedle fabrication. Microneedles were coated with F4 (small-
pox + PVA + trehalose) three times, dried using different methods, and subjected to virus
quantification. As shown in Figure 3, the viral titer of the vacuum-dried microneedles
was significantly higher than that of the naturally dried microneedles, suggesting that fast
drying would be beneficial in maintaining the stability of the vaccinia virus. Additionally,
we anticipate that the vacuum-dried samples would show better long-term stability than
the naturally dried samples due to lower moisture content, which is a key contributor to
vaccine stability [36]. When dried naturally, the moisture contained in the coating layer
evaporates slowly due to the lack of driving force and solidification of the coating surface.
In contrast, vacuum drying accelerates moisture evaporation and lowers the moisture
content in the coating layer compared to natural drying. Low moisture content in the
coating layer decreases the mobility of the vaccine, contributing to the stabilization of the
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vaccine in the dried state. Moreover, a previous study suggested that slow drying could
cause denaturation of virus, thereby lowering the potency of the smallpox vaccine [37].
3.2. Influence of Excipients on Vaccine Storage Stability
We further examined the stability of the vaccine during storage when formulated with
the excipients. Since our preliminary stability study using a PLA chip that mimics the
surface of microneedle showed that trehalose is beneficial in maintaining the stability of
the smallpox vaccine when stored at 4 ◦C for 30 days (Figure S1), we prepared vaccine-
coated microneedles with the formulations containing trehalose, stored them at 4 ◦C and
−20 ◦C for 30 days, and examined the change in viral titers. When stored at 4 ◦C for
30 days, there was no detectable titer in the samples without excipients (Figure 4, group a),
whereas the samples containing excipients showed measurable titers (Figure 4, groups b
and c). In particular, the formulation containing the combination of PVA and trehalose had
less loss of titer than the formulation of trehalose alone (Figure 4, group c). We anticipate
that the addition of polymers, such as PVA, would delay the crystallization of trehalose
during storage, maximizing the stabilizing effect of trehalose [38].




Figure 2. Virus titers of (a) smallpox vaccine (F1) (liquid), (b) smallpox vaccine + polyvinyl alcohol 
(F2) (PVA; liquid), (c) smallpox vaccine (F1) (reconstituted after solidification), (d) smallpox vac-
cine + PVA (F2) (reconstituted after solidification), and (e) smallpox vaccine + PVA + trehalose (F4) 
(reconstituted after solidification). Dotted line indicates the estimated virus titer. Statistical signifi-
cance compared to liquid smallpox vaccine (a) was determined using Student’s t-test (*** p < 
0.001). 
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Figure 2. Virus titers of (a) smallpox vaccine (F1) (liquid), (b) smallpox vaccine + polyvinyl alcohol (F2) (PVA; liquid),
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(*** p < 0.001).
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Smallpox vaccine only (F1), (b) smallpox vaccine + trehalose (F3), and (c) smallpox vaccine + poly-
vinyl alcohol (PVA) + trehalose (F4). Dotted line indicates the targeted virus coating amount. Sta-
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0.001). 
3.3. Long-Term Stability Test 
Since the stability of vaccine-coated microneedles was well maintained at −20 °C for 
a month, we further examined the change in virus titer for 6 months under the same stor-
age conditions. For this study, the microneedles were coated with 3.3 × 105 PFU of the 
vaccinia virus, which is higher than the human dose (2.5 × 105 PFU), considering the typ-
ical delivery efficiency of microneedles (approximately 80%) [42,43]. PVA (5% w/v) and 
trehalose (15% w/v) were used as excipients, and the vaccine-coated microneedles were 
dried under vacuum to minimize virus titer reduction. As shown in Figure 5, the virus 
titer appeared to be slightly reduced during the first month of storage but there was no 
statistically significant difference. In addition, the virus titer was maintained over 6 
months. 
Figure 4. One-month storage stability of vaccine-coated microneedles stored at 4 ◦C and −20 ◦C. (a) Smallpox vaccine only
(F1), (b) smallpox vaccine + trehalose ( 3), and (c) smallpox vaccine + polyvinyl alcohol (PVA) + trehalose (F4). Dotted line
indicates the targeted virus coating amount. Statistical significance comp red to the Day 0 sample was determined by
a t-test (** p < 0.01, *** p < 0.001).
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Compared to the viral titer right after solidification, storage at −20 ◦C for 30 days
caused additional 56.7% reduction in titer (Figure 4, group a). This reduction may be due
to freeze–thaw stress and ice crystal formation during reconstitution and storage [39–41].
When trehalose was included in the vaccine formulation, the viral titer was well maintained
(Figure 4, group b and c), suggesting that trehalose acts as a good cryoprotectant for the
vaccina virus. Notably, the addition of PVA to the formulation appeared not to be effective
in retaining the virus titers under frozen storage conditions compared with the trehalose-
only formulation. However, the PVA–trehalose formulation showed improved storage
stability at 4 ◦C. We speculate that PVA might not be able to protect the virus from freeze–
thaw stress; however, it might be capable of reducing stress during reconstitution, resulting
in similar viral titer retention in both PVA-only and PVA–trehalose formulations stored
at −20 ◦C and better viral titer retention in the PVA-only formulation stored at 4 ◦C
(Figure S1).
3.3. Long-Term Stability Test
Since the stability of vaccine-coated microneedles was well maintained at −20 ◦C
for a month, we further examined the change in virus titer for 6 months under the same
storage conditions. For this study, the microneedles were coated with 3.3 × 105 PFU of
the vaccinia virus, which is higher than the human dose (2.5 × 105 PFU), considering the
typical delivery efficiency of microneedles (approximately 80%) [42,43]. PVA (5% w/v) and
trehalose (15% w/v) were used as excipients, and the vaccine-coated microneedles were
dried under vacuum to minimize virus titer reduction. As shown in Figure 5, the virus
titer appeared to be slightly reduced during the first month of storage but there was no
statistically significant difference. In addition, the virus titer was maintained over 6 months.




Figure 5. Long-term stability of smallpox-vaccine-coated microneedle stored at −20 °C. Statistical 
significance compared to the Day 0 sample was determined by a t-test. There is no statistically sig-
nificant difference (p = 0.860). 
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reports from the literature because of the limited amount of vaccine available for the ex-
periments. We anticipate that it would be possible to develop a thermostable smallpox-
vaccine-coated microneedle by exploring additional excipients and process parameters. 
For example, a lyophilized smallpox vaccine was reported to be stable for 12 months and 
4 months when stored at 22 °C and 37 °C, respectively [37]. 
3.4. Immunogenicity of Smallpox-Vaccine-Coated Microneedles in Mice 
To evaluate the efficacy of smallpox-vaccine-coated microneedles, mice (n = 5) were 
immunized with microneedles coated with 3.3 × 105 PFU vaccinia virus. Blank micronee-
dles were used as a control. Serum samples were collected at 1, 3, 6, 9, and 12 weeks after 
immunization, and neutralizing antibodies against the vaccinia virus were analyzed by 
PRNT. As shown in Figure 6a, neutralizing antibodies were elicited beginning 3 weeks 
after immunization and were maintained for 12 weeks. Furthermore, we examined cell-
mediated immune responses induced by microneedle vaccination (Figure 6b); 12 weeks 
after priming, splenocytes collected from the mice were stimulated with UV-inactivated 
vaccinia virus for 2 days, and IFN-γ-secreting cells were measured by the ELISPOT assay 
to analyze T cell-mediated immune responses. We observed a significant increase in the 
IFN-γ-secreting cells after vaccination with the microneedles compared to that in the 
blank microneedle injection group. These results indicate that smallpox-vaccine-coated 
microneedles could elicit both humoral and cellular immune responses with a single im-
munization at least for 12 weeks in mice. 
Figure 5. Long-term stabili y of sm llpox-vaccine-coated mi ro edle stored at −20 ◦C. Statistical significance compared to
the Day 0 sample was determin by a t-test. There is no statistically significant diff rence (p = 0.860).
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Although the current formulation was able to maintain the stability of the smallpox
vaccine coated on microneedles for up to 6 months at −20 ◦C, it will be desirable to
develop a highly stable formulation that can be stored at higher temperatures. In this study,
we selected 5% PVA and 15% trehalose as excipients on the basis of our previous results
and reports from the literature because of the limited amount of vaccine available for the
experiments. We anticipate that it would be possible to develop a thermostable smallpox-
vaccine-coated microneedle by exploring additional excipients and process parameters.
For example, a lyophilized smallpox vaccine was reported to be stable for 12 months and
4 months when stored at 22 ◦C and 37 ◦C, respectively [37].
3.4. Immunogenicity of Smallpox-Vaccine-Coated Microneedles in Mice
To evaluate the efficacy of smallpox-vaccine-coated microneedles, mice (n = 5) were
immunized with microneedles coated with 3.3 × 105 PFU vaccinia virus. Blank micronee-
dles were used as a control. Serum samples were collected at 1, 3, 6, 9, and 12 weeks after
immunization, and neutralizing antibodies against the vaccinia virus were analyzed by
PRNT. As shown in Figure 6a, neutralizing antibodies were elicited beginning 3 weeks
after immunization and were maintained for 12 weeks. Furthermore, we examined cell-
mediated immune responses induced by microneedle vaccination (Figure 6b); 12 weeks
after priming, splenocytes collected from the mice were stimulated with UV-inactivated
vaccinia virus for 2 days, and IFN-γ-secreting cells were measured by the ELISPOT assay
to analyze T cell-mediated immune responses. We observed a significant increase in the
IFN-γ-secreting cells after vaccination with the microneedles compared to that in the blank
microneedle injection group. These results indicate that smallpox-vaccine-coated micronee-
dles could elicit both humoral and cellular immune responses with a single immunization
at least for 12 weeks in mice.
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Figure 6. Humoral and cell-mediated immune responses after vaccination using microneedles. (a) PRNT50 titer of
neutralizing antibody against the vaccinia virus, and (b) interferon (IFN)-γ-secreting cells were evaluated using the enzyme-
linked immunospot (ELISPOT) assay for analyzing T-cell-mediated immune response. Horizontal bars in each graph
indicate geometric mean titer. Statistical significance compared to MN only group was determined by a t-test (* p < 0.05).
PRNT, plaque reduction neutralisation test; SFU, spot forming unit.
In some of the vaccinated mice, neutralizing antibodies were not induced and mini-
mal cell-mediated responses were observed. We speculate that variation in microneedle
insertion depth by the thumb pressure application technique might have attributed to the
difference in immune responses. A previous report showed that it is difficult to induce
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immune responses if vaccina virus is administered too deeply or too superficially [44].
We anticipate that this problem could be overcome by ensuring consistent needle insertion
depth, which would be feasible by adopting an applicator and adjusting the length of
microneedles.
Additional data are needed to evaluate whether microneedle vaccination is more effec-
tive than other vaccination methods such as IM and SC injection. Although most vaccines
are administered through IM or SC route, IM delivery of vaccinia virus was ineffective in
protecting against smallpox [45]. A previous study showed that skin scarification was the
most effective approach for eliciting memory T cell responses and generating neutralizing
antibodies against smallpox virus compared with IM, intradermal, intraperitoneal, and
SC injections [46]. We anticipate that smallpox vaccination using microneedles would
be a more effective and appropriate method than conventional needle injection methods
because appropriately designed microneedles could achieve both skin scarification and
intradermal injection.
4. Conclusions
In this study, we examined the feasibility of smallpox vaccination using microneedles.
Stability tests suggest that fabrication processes, such as thawing, mixing, coating, and dry-
ing, would adversely affect the virus viability, reducing the potency of live virus vaccines.
Our data indicate that fast drying processes, such as vacuum drying, would be helpful in
retaining the viability of the vaccina virus. The use of stabilizers did not effectively protect
the virus from degradation during solidification; however, it significantly helped maintain
the stability of the virus during storage. Therefore, exploring various combinations of
excipients that can minimize the stress induced during drying would enable us to improve
the vaccine stability during solidification. In addition, our stability data demonstrated
that the combination of PVA and trehalose is suitable for coating, and it can maintain the
virus titers up to 6 months when stored at −20 ◦C. Furthermore, the developed smallpox
vaccine-coated microneedle induced both humoral and cell-mediated immune responses
in the mice, suggesting the potential of smallpox vaccination by microneedles. Although
microneedles coated with the developed vaccine formulation would provide advantages
over lyophilized smallpox vaccines, including reduced storage space, single-dose form
for minimizing vaccine wastage and contamination, and less pain during administration,
it is highly desirable to develop a thermostable smallpox microneedle that can be stored at
elevated temperatures over extended periods of time. We expect that, compared to conven-
tional vaccination by bifurcated needles, microneedle-based smallpox vaccination would
not only provide less complicated vaccine administration with higher dosing accuracy but
also reduce economic burden associated with vaccine storage and distribution. In conclu-
sion, microneedles could serve as a potential alternative method for smallpox vaccination
and stockpiling and could allow us to respond rapidly to emergencies such as bioterrorism.
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